Related Experiment Videos
Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines
S Hougaard1, P Nørgaard, N Abrahamsen
1Section for Radiation Biology, The Finsen Center, University Hospital of Copenhagen, Denmark.
Abstract:
Transforming growth factor beta (TGF-beta) exerts a growth inhibitory effect on many cell types through binding to two types of receptors, the type I and II receptors. Resistance to TGF-beta due to lack of type II receptor (RII) has been described in some cancer types including small cell lung cancer (SCLC). The purpose of this study was to examine the cause of absent RII expression in SCLC cell lines. Northern blot analysis showed that RII RNA expression was very weak in 16 of 21 cell lines. To investigate if the absence of RII transcript was due to mutations, we screened the poly-A tract for mutations, but no mutations were detected. Additional screening for mutations of the RII gene revealed a GG to TT base substitution in one cell line, which did not express RII. This mutation generates a stop codon resulting in predicted synthesis of a truncated RII of 219 amino acids. The nature of the mutation, which has not previously been observed in RII, has been linked to exposure to benzo[a]-pyrene, a component of cigarette smoke. Since RII has been mapped to chromosome 3p22 and nearby loci are often hypermethylated in SCLC, it was examined whether the lack of RII expression was due to hypermethylation. Southern blot analysis of the RII promoter did not show altered methylation patterns. The restriction endonuclease pattern of the RII gene was altered in two SCLC cell lines when digested with Smal. However, treatment with 5-aza-2'-deoxycytidine did not induce expression of RII mRNA. Our results indicate that in SCLC lack of RII mRNA is not commonly due to mutations and inactivation of RII transcription was not due to hypermethylation of the RII promoter or gene. Thus, these data show that in most cases of the SCLC cell lines, the RII gene and promoter is intact in spite of absent RII expression. However, the nature of the mutation found could suggest that it was caused by cigarette smoking.
Insights
Transforming growth factor beta receptor II (RII) is often absent in small cell lung cancer (SCLC). This study found RII absence is rarely due to mutations or promoter hypermethylation in SCLC cell lines.
Area of Science:
- Molecular Biology
- Oncology
- Cancer Research
Background:
- Transforming growth factor beta (TGF-beta) inhibits cell growth via type I and II receptors.
- Lack of TGF-beta receptor II (RII) expression is observed in some cancers, including small cell lung cancer (SCLC).
Purpose of the Study:
- To investigate the molecular mechanisms underlying the absent RII expression in SCLC cell lines.
Main Methods:
- Northern blot analysis to assess RII RNA expression.
- Screening for mutations in the RII gene and its poly-A tract.
- Southern blot analysis to evaluate RII promoter methylation.
- Treatment with 5-aza-2'-deoxycytidine to assess RII expression induction.
Main Results:
- RII RNA expression was very weak in 16 of 21 SCLC cell lines.
- No mutations were detected in the RII poly-A tract; one cell line had a GG to TT substitution causing a premature stop codon.
- RII promoter methylation patterns were not altered, and RII gene expression was not induced by demethylation treatment.
Conclusions:
- Absent RII mRNA expression in SCLC is not commonly caused by mutations or promoter hypermethylation.
- In most SCLC cell lines, the RII gene and promoter appear intact despite absent RII expression.
- A specific RII mutation identified may be linked to benzo[a]-pyrene exposure from cigarette smoke.